489 results on '"Alloway, Rita R"'
Search Results
2. Precision Medicine in Nephrology: An Integrative Framework of Multidimensional Data in the Kidney Precision Medicine Project
3. Molecular Signatures of Glomerular Neovascularization in a Patient with Diabetic Kidney Disease
4. Participant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project
5. The expanded role of the transplant pharmacist: A 10-year follow-up
6. Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates
7. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial
8. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis
9. Monoclonal Antibodies in Solid Organ Transplantation
10. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients
11. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial
12. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells
13. A prospective, iterative, adaptive trial of carfilzomib-based desensitization
14. Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation
15. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values
16. Immunosuppression for Liver Retransplantation: Babel Revisited
17. Chronopharmacokinetics and Food-Effects of Single-Dose LCP-tacrolimus in Healthy Volunteers
18. Reducing Donor Specific Antibody During Acute Rejection Diminishes Long Term Renal Allograft Loss: Comparison of Early and Late Rejection
19. High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression
20. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians.
21. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection
22. Single cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality
23. A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease
24. Effects of In Vivo CXCR4 Blockade and Proteasome Inhibition on Bone Marrow Plasma Cells in HLA-Sensitized Kidney Transplant Candidates
25. Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu
26. Single cell transcriptomic analysis of renal allograft rejection reveals novel insights into intragraft TCR clonality
27. Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations
28. Monoclonal Antibodies in Solid Organ Transplantation
29. Management of Antibody-Mediated Rejection in Transplantation
30. Mounting Clinical Evidence With Tacrolimus Generic Products
31. Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation
32. Proteasome Inhibition for Antibody-Mediated Allograft Rejection
33. Proteasome inhibitor-based therapy for antibody-mediated rejection
34. Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation
35. Belatacept Removal by Plasmapheresis: Dose Adjustments and Clinical Recommendations.
36. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups
37. PLASMA CELL BIOLOGY: FOUNDATIONS FOR TARGETED THERAPEUTIC DEVELOPMENT IN TRANSPLANTATION: Plasma cells in transplantation
38. Effects of invivoCXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates
39. Off-Label Use of Immunosuppressive Agents in Solid Organ Transplantation
40. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis
41. Immunosuppression for Liver Retransplantation: Babel Revisited
42. Plasma cell biology: Foundations for targeted therapeutic development in transplantation
43. Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
44. sj-pdf-3-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
45. sj-pdf-8-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
46. sj-docx-2-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
47. sj-docx-1-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
48. sj-docx-3-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
49. sj-pdf-4-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
50. sj-docx-4-mpp-10.1177_23814683211056537 ��� Supplemental material for Incorporating Patients��� Values and Preferences Into Decision Making About Transplantation of HCV-Na��ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.